Cargando…

Factors predicting the active treatment of renal angiomyolipoma: 30 years of experience in two tertiary referral centers

INTRODUCTION AND OBJECTIVE: This study aimed to identify clinical features representing predictive factors of active treatment (AT) compared to active surveillance (AS) for renal angiomyolipoma (AML). PATIENTS AND METHODS: From 1990 to 2020, patients referred to two institutions for a renal mass and...

Descripción completa

Detalles Bibliográficos
Autores principales: Daché, Arnaud, Fatica, Richard, Herts, Brian R., McLennan, Gordon, Remer, Erick M., Haber, Georges-Pascal, Ouzaid, Idir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210137/
https://www.ncbi.nlm.nih.gov/pubmed/37251582
http://dx.doi.org/10.3389/fsurg.2023.1094806
_version_ 1785047003349123072
author Daché, Arnaud
Fatica, Richard
Herts, Brian R.
McLennan, Gordon
Remer, Erick M.
Haber, Georges-Pascal
Ouzaid, Idir
author_facet Daché, Arnaud
Fatica, Richard
Herts, Brian R.
McLennan, Gordon
Remer, Erick M.
Haber, Georges-Pascal
Ouzaid, Idir
author_sort Daché, Arnaud
collection PubMed
description INTRODUCTION AND OBJECTIVE: This study aimed to identify clinical features representing predictive factors of active treatment (AT) compared to active surveillance (AS) for renal angiomyolipoma (AML). PATIENTS AND METHODS: From 1990 to 2020, patients referred to two institutions for a renal mass and diagnosed with an AML based on typical features on CT were included in the analysis. The study population was divided into two groups based on the treatment received: active surveillance (AS) or active treatment (AT). Age, gender, tuberous sclerosis syndrome, tumor size, contralateral kidney disease, renal function, year of diagnosis, and symptoms at presentation were assessed as potential predictive factors of active treatment using a logistic regression model in univariate and multivariate analyses. RESULTS: In total, 253 patients (mean age 52.3 ± 15.7 years; 70% women; 70.9% incidentally diagnosed) were included in the analysis. One hundred and nine (43%) received AS, whereas 144 (57%) were actively treated. For univariate analysis, age, tuberous sclerosis complex syndrome, tumor size, symptoms at presentation, and contralateral kidney disease were found to be predictors of AT. Only tumor size (p < 0.001) and the year of diagnosis (p < 0.001) remained significant for multivariable analyses. The likelihood of being managed with AS evolved over the study period and was 50% and 75% when diagnosed before and after 2010, respectively. With respect to size, 4-cm and 6-cm tumors had a probability of 50% and 75% of being treated with AS, respectively. CONCLUSION: The present analysis from a high-volume institution provides evidence that the management of renal masses with typical radiological features of AML has markedly changed over the last three decades with a trend toward AS over AT. Tumor size and the year of diagnosis were significant factors for the treatment strategies.
format Online
Article
Text
id pubmed-10210137
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102101372023-05-26 Factors predicting the active treatment of renal angiomyolipoma: 30 years of experience in two tertiary referral centers Daché, Arnaud Fatica, Richard Herts, Brian R. McLennan, Gordon Remer, Erick M. Haber, Georges-Pascal Ouzaid, Idir Front Surg Surgery INTRODUCTION AND OBJECTIVE: This study aimed to identify clinical features representing predictive factors of active treatment (AT) compared to active surveillance (AS) for renal angiomyolipoma (AML). PATIENTS AND METHODS: From 1990 to 2020, patients referred to two institutions for a renal mass and diagnosed with an AML based on typical features on CT were included in the analysis. The study population was divided into two groups based on the treatment received: active surveillance (AS) or active treatment (AT). Age, gender, tuberous sclerosis syndrome, tumor size, contralateral kidney disease, renal function, year of diagnosis, and symptoms at presentation were assessed as potential predictive factors of active treatment using a logistic regression model in univariate and multivariate analyses. RESULTS: In total, 253 patients (mean age 52.3 ± 15.7 years; 70% women; 70.9% incidentally diagnosed) were included in the analysis. One hundred and nine (43%) received AS, whereas 144 (57%) were actively treated. For univariate analysis, age, tuberous sclerosis complex syndrome, tumor size, symptoms at presentation, and contralateral kidney disease were found to be predictors of AT. Only tumor size (p < 0.001) and the year of diagnosis (p < 0.001) remained significant for multivariable analyses. The likelihood of being managed with AS evolved over the study period and was 50% and 75% when diagnosed before and after 2010, respectively. With respect to size, 4-cm and 6-cm tumors had a probability of 50% and 75% of being treated with AS, respectively. CONCLUSION: The present analysis from a high-volume institution provides evidence that the management of renal masses with typical radiological features of AML has markedly changed over the last three decades with a trend toward AS over AT. Tumor size and the year of diagnosis were significant factors for the treatment strategies. Frontiers Media S.A. 2023-05-11 /pmc/articles/PMC10210137/ /pubmed/37251582 http://dx.doi.org/10.3389/fsurg.2023.1094806 Text en © 2023 Daché, Fatica, Herts, McLennan, Remer, Haber and Ouzaid. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Surgery
Daché, Arnaud
Fatica, Richard
Herts, Brian R.
McLennan, Gordon
Remer, Erick M.
Haber, Georges-Pascal
Ouzaid, Idir
Factors predicting the active treatment of renal angiomyolipoma: 30 years of experience in two tertiary referral centers
title Factors predicting the active treatment of renal angiomyolipoma: 30 years of experience in two tertiary referral centers
title_full Factors predicting the active treatment of renal angiomyolipoma: 30 years of experience in two tertiary referral centers
title_fullStr Factors predicting the active treatment of renal angiomyolipoma: 30 years of experience in two tertiary referral centers
title_full_unstemmed Factors predicting the active treatment of renal angiomyolipoma: 30 years of experience in two tertiary referral centers
title_short Factors predicting the active treatment of renal angiomyolipoma: 30 years of experience in two tertiary referral centers
title_sort factors predicting the active treatment of renal angiomyolipoma: 30 years of experience in two tertiary referral centers
topic Surgery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210137/
https://www.ncbi.nlm.nih.gov/pubmed/37251582
http://dx.doi.org/10.3389/fsurg.2023.1094806
work_keys_str_mv AT dachearnaud factorspredictingtheactivetreatmentofrenalangiomyolipoma30yearsofexperienceintwotertiaryreferralcenters
AT faticarichard factorspredictingtheactivetreatmentofrenalangiomyolipoma30yearsofexperienceintwotertiaryreferralcenters
AT hertsbrianr factorspredictingtheactivetreatmentofrenalangiomyolipoma30yearsofexperienceintwotertiaryreferralcenters
AT mclennangordon factorspredictingtheactivetreatmentofrenalangiomyolipoma30yearsofexperienceintwotertiaryreferralcenters
AT remererickm factorspredictingtheactivetreatmentofrenalangiomyolipoma30yearsofexperienceintwotertiaryreferralcenters
AT habergeorgespascal factorspredictingtheactivetreatmentofrenalangiomyolipoma30yearsofexperienceintwotertiaryreferralcenters
AT ouzaididir factorspredictingtheactivetreatmentofrenalangiomyolipoma30yearsofexperienceintwotertiaryreferralcenters